AzTrials
AzTrials

Global Warming Effect of Nitrous OxidePhase 4NCT05430750

Global Warming Impact of Nitrous Oxide

A Phase 4 study testing Nitrous oxide and Sevoflurane in people with Global Warming Effect of Nitrous Oxide, run by Sir Ganga Ram Hospital at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Environmental hazards of human activity are a topic of present day world, global warming being one of the leading concerns. Gases that contribute to this are greenhouse gases. Nitrous oxide (N2O) is a greenhouse gas that is commonly used in medical practice, mostly confined to provision of anaesthesia during surgical… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Global Warming Effect of Nitrous Oxide
What is being tested?
Nitrous oxide and Sevoflurane
Could I receive a placebo?
No, everyone receives an active treatment
How many people
102 participants
Where
1 siteIndia
Study dates
29 Jun 2022to 22 Apr 2023
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years
  • ASA physical status I and II
  • Patients undergoing elective non-laparoscopic surgeries of minimum 1 hour duration without use of adjuvant central neuraxial or peripheral nerve block under general anaesthesia

Who cannot join

  • Failure to obtain consent
  • Neurological disorders (previous neurosurgery , psychiatric disorders, autonomic system disorders - orthostatic hypotension, transient ischemic attacks )
  • Cardiovascular disorders (uncontrolled hypertension, A-V block, sinus bradycardia, congenital heart disease, reduced LV compliance and diastolic dysfunction)
  • Hepatorenal insufficiency
  • Uncontrolled endocrine disorders (diabetes mellitus, hypothyroidism, hyperthyroidism)
  • Electrolyte disturbances (hyponatremia, hypernatremia)
Show all 10Show fewer
  • Pulmonary dysfunction (restrictive /obstructive lung disease)
  • Acute /chronic drug dependence /substance abuse
  • Closed cavity surgeries (middle ear surgeries, eye surgeries)
  • Previous h/o PONV

Trial locations and contacts

1 site in 1 country.

India1 site
  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, 110060

Other trials in India

About this study

Official title: Global Warming Impact and Clinical Effects of a Novel 'streamed-in' Nitrous Oxide Administration as a Carrier Gas During Sevoflurane General Anaesthesia: a Randomized Pilot Study

Environmental hazards of human activity are a topic of present day world, global warming being one of the leading concerns. Gases that contribute to this are greenhouse gases. Nitrous oxide (N2O) is a greenhouse gas that is commonly used in medical practice, mostly confined to provision of anaesthesia during surgical procedures in the operation theatre. N2O is not a potent anesthetic, and is used as a carrier for volatile anesthetic during general anaesthesia. This is to reduce the use of volatile anesthetics and other analgesic drugs while maintaining adequate depth of anaesthesia and analgesia. The N2O gas that is used during general anaesthesia is scavenged and released into the atmosphere without any processing. In the atmosphere it stays and produces deleterious greenhouse effect primarily owing to its long lifetime of 114 years. In addition, it also causes depletion of ozone layer. The green house effect of gases is evaluated and compared with the use of carbon-di-oxide equivalents (CDE). When the effects are considered for 20 years it is termed CDE20.The efforts to reduce these harmful effects can be directed towards reduction/cessation of N2O use, or its post anesthetic processing. The long history of its use in clinical practice and benefits such as analgesia for various procedures; makes it difficult to be completely taken out of usage in the present day anaesthesia practice. Though processing of N2O after use during GA is possible, it's impractical because of cost efficiency. We therefore, have directed our focus on further reducing its consumption while being used for GA. Low- flow anaesthesia has been in practice for the same reason (i.e. to reduce the wastage of gases).

This study is aimed to reduce the N2O consumption even further by employing a novel 'streamed-in' technique of N2O administration during low-flow GA. Conventionally, N2O use is initiated during the initial high fresh gas flows (FGF) before shifting to low-flow ventilation. 'Streamed-in' N2O administration strategy employs initiation of N2O into FGF after the institution of low-flow anaesthesia. Hence, the participants are not exposed to an unconventional drug or a new route of its administration, but an alternate strategy to its conventional use. We aim to evaluate the novel technique of 'streamed-in' N2O during sevoflurane GA for its global warming effects (in terms of CDE20) and its clinical effects ( intraoperative general anaesthesia state, hemodynamic profile) and post operative effects( postoperative nausea vomiting -PONV, postoperative pain profile- numerical rating scale-NRS)

Read the detailed description

Earliest use of nitrous oxide (N2O) in medical practice dates back to 1884. It aimed at providing analgesia during surgical procedure. Over the years the N2O use for anaesthesia evolved with the knowledge that it has very low anesthetic potential and high minimum alveolar concentration (MAC =104%), and therefore it cannot be used as a sole anesthetic. This led to N2O being used a carrier gas only during inhalational vapor (sevoflurane, isoflurane, desflurane) anaesthesia. The N2O- vapor co-administration not only reduces inhaled vapor requirements but also offers continuous analgesia state during maintenance of anaesthesia. Studies show its use in sedation and analgesia for labor analgesia and other minor procedures especially in pediatric population, such as, venipuncture, venous cannulation, fracture reduction, lumbar puncture, acute pain etc. Further, the use of intraoperative N2O also reduces the incidence of patients developing chronic postoperative pain.

The use of N2O, with attendant application advantages come the disadvantages of having undesirable effect on the patient (diffusion hypoxia, PONV), the medical care provider (megaloblastic anemia, risk of spontaneous abortion, reduced fertility) and environment (global warming). N2O possesses greenhouse effect defined in terms of global warming potential (GWP) [20 year GWP and 100year GWP - 289 (GWP20) and 298 (GWP100), respectively] and 'ozone depleting' properties. The above stated effects in conjunction with long life-span of N2O (114 years) in the atmosphere is likely to lead to longstanding negative environmental impact if its use is not stopped/made more efficient. Therefore, there is an absolute need for using N2O more efficiently for reducing effects on the patients, the first to get exposed operative room personnel, and ambient environment at large.

Sevoflurane is an inhalational anesthetic with a sweet smell, fast onset, offset and a good safety profile. Sevoflurane is also a greenhouse gas. Its use in combination with N2O is in practice for the benefits discussed earlier.

Having been in medical use for over 150 years with its various benefits, the use of N2O cannot be expected to be abandoned in the near future. Though steps to reduce anesthetic gas usage with techniques such as low-flow anaesthesia (fresh gas flow-FGF<alveolar ventilation, arbitrarily taken as 2L/min) and safer carbon-di-oxide absorbers are in vogue; no further/specific exploration has been undertaken. With Sevoflurane, use of fresh gas flows less than 1L/min is not recommended due to concerns surrounding production of Compound A and its nephrotoxic effects (clinically unproven in human ).

Inhalational anesthetics are almost completely excreted through lungs via exhalation without undergoing significant metabolism. Even ex-vivo inhalational agents are not processed, but only collected through scavenging system and released into the atmosphere. 15 The use of N2O with inhalational anesthetics leaves a far greater impact on the environment when compared to their use with air/O2. Though N2O's pound-for- pound impact in terms of global warming (GWP20-289) is less when compared to other inhalational anesthetics in use [ isoflurane (GWP20-1401), sevoflurane (GWP20-349), desflurane (GWP20-3714)]; it has a more significant impact on environment mainly because of the much higher consumption volume and also the fact that it is a 'stock' pollutant i.e. has a long lifetime and accumulates overtime. In contrast, inhalational anesthetics which are 'flow' pollutants i.e. have short lifetime and doesn't accumulate as long as new release into atmosphere is kept constant. The global warming impact of gases is evaluated and compared by the CO2 equivalents (CDE) produced. CDE20 (Anesthetic gas quantity in grams *GWP20), takes into account both the GWP and the quantity of the gas that is produced. The GWP and CDE are calculated for a defined duration of time. Commonly implemented in case of inhalational anesthetic is for 20 years, as the atmospheric lifetime of inhalational anesthetics is less than 20 years.

With the growing concern for global warming and impact of human activity on the earth's ecology; medical fraternity should be at the forefront of new developments that work towards these issues. With the subject at hand the investigators are attempting to reduce the medical use of N2O and in turn its effects on the environment by evaluating a novel method of N2O use. We expect it to reduce the N2O consumption significantly enough to lessen its harmful global ecological impact.

Conventional low-flow anaesthesia with N2O is implemented by using FGF of about ≥4L/m (O2 + N2O) initially. Once desired anesthetic gas composition is attained in the system and the minimum alveolar concentration reflects adequacy of anesthetic depth (i.e. MAC 0.7-1.3), FGF is reduced to the low-flow i.e. ≤1.0 Liters/min.

Though there is evidence to negative environmental effects of inhaled anesthetic vapor and N2O, they have been largely based on theoretical methodology. To the best of our knowledge, till date there are no studies that have evaluated the global warming effects of inhaled GA (with and without N2O) on real use-in patient scenarios. Given that different patients may have different anesthetic uptake (N2O, inhaled vapor) characteristics with different strategies of GA, the consequent environmental effect may be variable, and therefore, must be quantified and controlled.

In this proposed study, the investigators aim to evaluate a novel technique of N2O administration i.e. "streamed-in" administration technique in terms of its global warming impact and clinical effects. Initially, air-O2-sevoflurane is introduced at high FGF of 3.0 L/min. Once the target anesthetic gas concentration is attained in the system i.e. MAC 0.5, FGF is reduced to achieve a low-flow state. At this point N2O is "streamed-in" to add to O2-sevoflurane mixture.

Being tested
Nitrous oxide, Sevoflurane
Keywords
nitrous oxide, sevoflurane, global warming

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nitrous oxideDrug

    In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.

  • Nitrous oxideDrug

    In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.

  • SevofluraneDrug

    Ventilation will be initiated with 2% sevoflurane in all the groups

Study groups in NCT05430750
Study groupRoleWhat they receive
Conventional' - N2O carrier gas groupActive comparatorVentilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min (Low flow) and allowed to reach MAC 1.0 before incision is allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
Receives: Drug: Nitrous oxide; Drug: Sevoflurane
'Streamed -in' N2O carrier gas groupActive comparatorVentilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %. When MAC 1.0 is reached incision will be allowed. At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the N2O - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
Receives: Drug: Nitrous oxide; Drug: Sevoflurane
Non-N2O groupActive comparatorVentilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow). The incision is allowed when MAC 1.0 is achieved .At 20-minutes time point post induction if MAC 1.0 is not achieved at 2% sevoflurane then the sevoflurane vaporizer concentration will be adjusted to achieve MAC 1.0, before incision is allowed. Anaesthesia will be maintained at MAC 1.0 throughout. After surgery is over, the O2 - Sevoflurane will be stopped and FGF increased to 3.0L with 100% O2.
Receives: Drug: Sevoflurane

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Carbon-di-oxide equivalent -20 years (CDE20)

    Carbon-di-oxide equivalent -20 years of nitrous oxide \& sevoflurane will be calculated using the formula Mass of Anaesthetic used *GWP20 (Global Warming Potential -20 years)

    Measured: From start of anesthesia till 5- minutes post extubation

Secondary outcomes (9)
  1. Intraoperative End-tidal anaesthesia gas (ETAG) concentration

    ETAG concentration of nitrous oxide, sevoflurane, oxygen, carbon dioxide will be recorded from the patient monitor

    Measured: From start of anesthesia till 5- minutes post extubation

  2. Intraoperative minimum alveolar concentration (MAC)

    MAC will be recorded from the patient monitor

    Measured: From start of anesthesia till 5- minutes post extubation

  3. Intraoperative consumption of anesthetic gases

    Intraoperative consumption of nitrous oxide, sevoflurane, oxygen and air will be noted at the end of anesthesia from the log book of the anesthesia machine

    Measured: From start of anesthesia till 5- minutes post extubation

  4. Changes in intra-operative heart rate (beats per minute)

    Comparison of intra-operative heart rate will be done among the three groups

    Measured: From start of anesthesia till 5- minutes post extubation

  5. Change in Intra-operative blood pressure - systolic , diastolic, and mean (mmHg)

    Comparison of intra-operative blood pressure- systolic, diastolic, and mean will be done among the three groups

    Measured: From start of anesthesia till 5- minutes post extubation

  6. Changes in rate pressure product

    Comparison of rate pressure product will be done among the three groups. Rate pressure product will be calculated using the formula :Systolic blood pressure *heart rate /1000

    Measured: From start of anesthesia till 5- minutes post extubation

  7. Postoperative Nausea and Vomiting (PONV)

    PONV will be assessed using postoperative nausea and vomiting (PONV) Scale. The scale measures PONV on a scale of 0 to 2. A score of '0' indicates that the patient has no emetic symptoms, whereas a score of '2' indicates that the patient has vomiting.

    Measured: From end of anaesthesia till 24-hours postoperatively

  8. Postoperative pain

    Postoperative pain will be assessed using the 10-point numerical rating scale. The scale has scoring from 0 to 10. '0' implying minimum pain \& '10' implying maximum pain

    Measured: From end of anaesthesia till 24-hours postoperatively

  9. Incidence of intraoperative awareness

    Awareness will be assessed using 5-question based Brice Structured Interview

    Measured: From end of anaesthesia till 24-hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2022
  2. Study start29 Jun 2022
  3. Primary completion22 Apr 2023
  4. Study completion22 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
One hundred and two patients of either sex, and schedule for elective surgery under general anesthesia (GA) will be randomly divided into three groups of 34-each. Group 1('Conventional' N2O carrier gas group) Ventilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min. Group 2 ('Streamed-in' N2O carrier gas group) Ventilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %. Group 3 (Non-N2O group) Ventilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow).
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
102 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05430750
Sponsor's protocol ID
EC/05/22/2063
Status last verified
Aug 2023
First submitted
18 Jun 2022
Last updated
9 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Nitrous oxide and Sevoflurane in people with Global Warming Effect of Nitrous Oxide, run by Sir Ganga Ram Hospital at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Carbon-di-oxide equivalent -20 years (CDE20) (time frame: From start of anesthesia till 5- minutes post extubation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in